These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 32267732)

  • 1. Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.
    Roden DM; Harrington RA; Poppas A; Russo AM
    Circulation; 2020 Jun; 141(24):e906-e907. PubMed ID: 32267732
    [No Abstract]   [Full Text] [Related]  

  • 2. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.
    Chorin E; Dai M; Shulman E; Wadhwani L; Bar-Cohen R; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Chinitz LA; Jankelson L
    Nat Med; 2020 Jun; 26(6):808-809. PubMed ID: 32488217
    [No Abstract]   [Full Text] [Related]  

  • 3. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
    Roden DM; Harrington RA; Poppas A; Russo AM
    Heart Rhythm; 2020 Jul; 17(7):e231-e232. PubMed ID: 32302703
    [No Abstract]   [Full Text] [Related]  

  • 4. Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment.
    Roden DM; Harrington RA; Poppas A; Russo AM
    J Am Coll Cardiol; 2020 May; 75(20):2623-2624. PubMed ID: 32283123
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
    Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
    Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
    Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
    Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
    Juurlink DN
    CMAJ; 2020 Apr; 192(17):E450-E453. PubMed ID: 32269021
    [No Abstract]   [Full Text] [Related]  

  • 8. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
    Bun SS; Taghji P; Courjon J; Squara F; Scarlatti D; Theodore G; Baudouy D; Sartre B; Labbaoui M; Dellamonica J; Doyen D; Marquette CH; Levraut J; Esnault V; Bun SS; Ferrari E
    Clin Pharmacol Ther; 2020 Nov; 108(5):1090-1097. PubMed ID: 32588427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemic.
    Capucci A; Santarelli A; Bartolomei M; Paolizzi C; Biagetti C; Dappozzo A; Piovaccari G
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):922-923. PubMed ID: 32740441
    [No Abstract]   [Full Text] [Related]  

  • 10. Saudi Heart Rhythm Society Task Force on Management of Potential Arrhythmogenicity Associated with Pharmacotherapy for COVID-19.
    AlShoaibi NA; Maghrabi K; Alanazi H; Harbi MA; Alghamdi S
    Ann Saudi Med; 2020; 40(5):365-372. PubMed ID: 32954790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
    Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
    Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
    Monzani A; Genoni G; Scopinaro A; Pistis G; Kozel D; Secco GG
    Eur J Clin Invest; 2020 Jun; 50(6):e13258. PubMed ID: 32356580
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mercuro NJ; Yen CF; Shim DJ; Maher TR; McCoy CM; Zimetbaum PJ; Gold HS
    JAMA Cardiol; 2020 Sep; 5(9):1036-1041. PubMed ID: 32936252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection.
    Voisin O; Lorc'h EL; Mahé A; Azria P; Borie MF; Hubert S; Ménage E; Guillerm JC; Mourad JJ
    Mayo Clin Proc; 2020 Aug; 95(8):1696-1700. PubMed ID: 32753141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
    Naksuk N; Lazar S; Peeraphatdit TB
    Eur Heart J Acute Cardiovasc Care; 2020 Apr; 9(3):215-221. PubMed ID: 32372695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.
    Gunay S; Caliskan S; Sigirli D; Sahin E
    Bratisl Lek Listy; 2020; 121(11):817-821. PubMed ID: 33164544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients.
    Rani S; Grover S; Mehra A; Sahoo S
    Indian J Pharmacol; 2020; 52(3):229-231. PubMed ID: 32874009
    [No Abstract]   [Full Text] [Related]  

  • 18. Temporal Trends in Arrhythmogenicity Related to Treatment of COVID-19 Infection.
    Hummel JP; Maraj I; Taoutel R; Chamoun R; Workman VK; Tran L; Abboud JM; Afif C; Chouairi S; Delvecchio A; Howes CJ; Enriquez AD; Akar JG
    Circ Arrhythm Electrophysiol; 2020 Oct; 13(10):e008841. PubMed ID: 32931318
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
    Funck-Brentano C; Salem JE; Nguyen LS; Drici MD; Roden DM
    Arch Cardiovasc Dis; 2020 May; 113(5):367-368. PubMed ID: 32331979
    [No Abstract]   [Full Text] [Related]  

  • 20. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
    Chorin E; Wadhwani L; Magnani S; Dai M; Shulman E; Nadeau-Routhier C; Knotts R; Bar-Cohen R; Kogan E; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Stefano C; Chinitz LA; Jankelson L
    Heart Rhythm; 2020 Sep; 17(9):1425-1433. PubMed ID: 32407884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.